Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed relapsed or refractory grade I, II, or III non-Hodgkin's lymphoma (NHL), including follicular, small lymphocytic, or marginal zone/MALT lymphoma
• Previously treated with radiotherapy, immunotherapy, and/or chemotherapy for NHL
• * Progression of disease or no response since last treatment for NHL
• 1D10+ lymphoma by immunohistochemistry or flow cytometry
• Bidimensionally measurable disease at least 2 cm in a single dimension
• No CNS metastases
• Circulating tumor cells no greater than 5,000/mm\^3
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• ECOG 0-2
• Life expectancy:
• At least 3 months
• Hematopoietic:
• Platelet count at least 75,000/mm\^3 (unless disease related)
• Neutrophil count at least 1,000/mm\^3 (unless disease related)
• Hemoglobin greater than 8.0 g/dL
• Hepatic:
• Bilirubin less than 2.5 mg/dL
• SGOT less than 4 times upper limit of normal
• Renal:
• Creatinine less than 2.5 mg/dL
• Cardiovascular:
• No clinically significant cardiac disease (New York Heart Association class III or IV)
• No evidence of myocardial infarction or cardiac arrhythmia (unless surgically repaired) within the past 6 months
• Pulmonary:
• No clinically significant pulmonary disease
• Other:
• No other malignancy within the past 2 years except non-melanoma skin cancer or carcinoma in situ
• No significant psychiatric or CNS impairment
• No active serious infection
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 1 month after study
• Negative anti-Hu1D10 antibody response (HAHA/HAMA)
• HIV negative
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• See Disease Characteristics
• At least 4 weeks since prior interferon therapy
• At least 3 months since prior immunotherapy
• No prior monoclonal antibody Hu1D10
• Chemotherapy:
• See Disease Characteristics
• At least 4 weeks since prior cytotoxic chemotherapy
• Endocrine therapy:
• At least 4 weeks since prior corticosteroids (more than 10 mg prednisone/day)
• No concurrent corticosteroids at more than 10 mg prednisone/day for pre-existing diseases or adverse reactions
• Radiotherapy:
• See Disease Characteristics
• At least 4 weeks since prior external beam radiotherapy
• At least 3 months since prior radioimmunotherapy
• Surgery:
• Not specified
• Other:
• No other concurrent lymphoma therapy